



# SSAI ANNUAL CONGRESS 2025

## IMMUNOLOGY 2025: FROM LAKE LEMAN TO NEW HORIZONS

AUGUST 28-29, 2025

BEAULIEU LAUSANNE

## Credits\*

	SSAI	FAMH	GST/SVS	SGAIM		SGDV/SSDV	SGM0/SSOM	SGR/SSR
28 August	6 Credits	6 Credits	6 Credits	6 Credits		3 Credits	5 Credits	6 Credits
29 August	6 Credits	6 Credits	6 Credits	6 Credits		6 Credits	5 Credits	6 Credits
Total	12 Credits	12 Credits	12 Credits	12 Credits		9 Credits	10 Credits	12 Credits

\*Additional credits are claimed to further societies



SAVE THE DATE



**28<sup>TH</sup> COURSE:  
ALLERGOLOGY AND IMMUNOLOGY UPDATE (AIU)**

**JANUARY 23-24, 2026  
INTERLAKEN**

© Congress Kursaal Interlaken

**SAVE  
THE  
DATE!**

Credits: Eventi e congressi, Città di Lugano

**SSAI ANNUAL CONGRESS AND  
SWISS AUTOIMMUNE LIVER DISEASE MEETING**  
**August 27-28, 2026 | Palazzo dei Congressi Lugano**



Société Suisse d'Allergologie et d'Immunologie  
Schweizerische Gesellschaft für Allergologie und Immunologie  
Swiss Society for Allergology and Immunology



Fondazione  
Epatocentro Ticino

## TABLE OF CONTENTS

<b>Welcome</b>	<b>4</b>
<b>Scientific Advisory Committee</b>	<b>4/5</b>
<b>Programme Overview</b>	<b>6</b>
<b>Scientific Programme</b>	<b>9</b>
<b>Congress Dinner</b>	<b>18</b>
<b>Awards 2025</b>	<b>22</b>
<b>Exhibition Plan</b>	<b>24</b>
<b>Sponsors / Exhibitors</b>	<b>25</b>
<b>General Information</b>	<b>26</b>

## WELCOME FROM THE PRESIDENTS OF THE ORGANISING COMMITTEE

Dear Friends and Colleagues,

We are delighted to invite you to the **Annual Congress of the Swiss Society for Allergology and Immunology (SGAI-SSAI)**, which will take place at Beaulieu palace in Lausanne on **August 28-29, 2025**. This year's congress, themed "Immunology 2025: From Lake Lemman to New Horizons", will highlight the latest advancements in the diagnosis and treatment of allergic and immunological conditions.

Esteemed speakers from around the world and Switzerland will share their expertise, providing valuable insights into groundbreaking research and innovative treatment approaches. Beyond the scientific sessions, the congress will offer ample opportunities for scientific discussions and networking, whether during the sessions, while exploring the poster exhibition or at the congress dinner. We will conclude the congress with the award ceremony and a keynote lecture.

We look forward to your participation in making this event a truly memorable and rewarding experience. Together with the organising committee, we are excited to welcome you to Lausanne for what promises to be an inspiring and dynamic gathering of minds.

With our warmest regards,

### Presidents of the Organising Committee



**Prof. Camillo Ribi**  
Physician in chief,  
Associate Professor  
CHUV | Lausanne University  
Hospital, Service of  
Immunology and Allergy



**Prof. Julia Esser-von Bieren**  
Associate Professor  
UNIL | University of Lausanne,  
Faculty of Biology and  
Medicine, Department of  
Immunobiology

## SCIENTIFIC ADVISORY COMMITTEE



**PD Dr Niki Ubags**

Division of Pulmonology, Department of Medicine, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL)



**Prof. Sanjiv Luther**

Department of Immunobiology, Faculty of Biology and Medicine, University of Lausanne (UNIL)



**Prof. Dela Golshayan**

Transplantation Center, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL)



**Prof. Ping-Chih Ho**

Department of Fundamental Oncology, Faculty of Biology and Medicine, University of Lausanne (UNIL), Ludwig Institute for Cancer Research at University of Lausanne (UNIL)



**Prof. Thierry Roger**

Infectious Diseases Service, Department of Medicine, Faculty of Biology and Medicine, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL)



**Prof. Matthieu Perreau**

Division of Immunology and Allergy, Lausanne University Hospital (CHUV)



**Prof. Yannick Muller**

Division of Immunology and Allergy, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL)



**Prof. Fabio Candotti**

Division of Immunology and Allergy, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL)

# PROGRAMME OVERVIEW – THURSDAY, AUGUST 28<sup>TH</sup>, 2025

	Rome	St. Moritz A	St. Moritz B	Turin AB			
09:00	09:00 – 09:45 Registration						
09:15							
09:30							
09:45							
09:50	09:50 – 11:00 Plenary 1 Autoimmunity						
10:00							
10:30							
10:45							
11:00		11:00 – 11:20 Coffee break with industry exhibition					
11:15							
11:20	11:20 – 12:30 Plenary 2 Host Immunity, Epithelial Barriers and Microbiome						
11:45							
12:00							
12:15							
12:30							
12:45	12:30 – 14:00 Lunch break with industry exhibition and poster viewing	13:00 – 13:45 Company Symposium 1 Otsuka Pharmaceutical (Switzerland) GmbH	12:45 – 13:45 Guided Poster Tour	13:00 – 13:45 Company Symposium 2 ALK-Abellö AG			
13:00							
13:15							
13:30							
13:45							
14:00	14:00 – 15:30 Parallel Session 1: Allergy (Respiratory)	14:00 – 15:30 Parallel Session 2: Tumor-Immunology		14:00 – 15:30 Parallel Session 3: Immune Defects			
14:15							
14:30							
14:45							
15:00							
15:15	15:30 – 16:00 Coffee break with industry exhibition						
15:30							
15:45							
16:00	16:00 – 17:00 Short Communication Session – Allergology				16:00 – 17:00 Short Communication Session – Clinical Immunology & Allergy		
16:15							
16:30							
16:45							
17:00	17:00 – 17:15 Room change						
17:15		17:15 – 18:15 SSAI General Assembly					
17:30							
17:45							
18:00	From 18:00 Congress Dinner at the «Olympic Museum Lausanne»						
18:15							
18:30							
18:45							
19:00							
19:15							
19:30							

Color legend:

Parallel Session	Company Symposia	Plenary Lecture	Short Communication	Poster
------------------	------------------	-----------------	---------------------	--------

# PROGRAMME OVERVIEW – FRIDAY, AUGUST 29<sup>TH</sup>, 2025

	Rome	St. Moritz A	St. Moritz B	Turin AB
08:15	08:15 – 09:00 Registration			
08:30				
08:45				
09:00	09:00 – 10:30 Parallel Session 6: Mucosal Immunity & Infection	09:00 – 10:30 Parallel Session 4: Neuro-Immunology		09:00 – 10:30 Parallel Session 5: Diagnostics
09:15				
09:30				
09:45				
10:00				
10:15				
10:30	10:30 – 11:00			
10:45	Coffee break with industry exhibition			
11:00	11:00 – 12:00 TARDOC – What to Expect – How to Prepare?	11:00 – 12:00 Short Communication Session – Basic Immunology		11:00 – 12:00 Short Communication Session – Translational
11:15				
11:30				
11:45				
12:00				
12:15				
12:30	12:30 - 13:15 Company Symposium 3 BioCryst Schweiz GmbH	12:30 - 13:15 Company Symposium 4 Stallergenes AG	12:15 - 13:15 Guided Poster Tour	12:00 – 13:30 Lunch break with industry exhibition
12:45				
13:00				
13:15				
13:30	13:30 – 15:00 Parallel Session 8: Novel Technologies in Immunology	13:30 – 15:00 Parallel Session 7: Hypersensitivity and Immune Regulation		13:30 – 14:30 Short Communication Session – SYIS
13:45				
14:00				
14:15				
14:30				
14:45				
15:00	15:00 - 15:15 Room change			
15:15	Award Ceremony			
15:30	15:30 – 16:40 Plenary 3 Keynote Lectures in Clinical Immunology			
15:45				
16:00				
16:15				
16:40	16:40 – 16:45 Closing			
16:45				
17:00				

Color legend:

Parallel Session	Company Symposia	Plenary Lecture	Short Communication	Poster
------------------	------------------	-----------------	---------------------	--------



# Bigger than allergies

Defy tree pollen and mite allergies with the help of a sublingual allergy immunotherapy<sup>1</sup>

**NEW**  
from the age of 5:  
SLIT\* for tree pollen  
or house dust mite  
allergies<sup>1</sup>

ITULAZAX<sup>®</sup>

ACARIZAX<sup>®</sup>

**Rise Above Allergies**  
ALK SLIT-tablets

\* SLIT = sublingual allergy immunotherapy. 1. See the currently approved information for healthcare professionals for ACARIZAX<sup>®</sup> and ITULAZAX<sup>®</sup> at [www.swissmedinfo.ch](http://www.swissmedinfo.ch) or listed below.

**Abridged Information for healthcare professionals ACARIZAX<sup>®</sup> and ITULAZAX<sup>®</sup>.** Comp.: Lyophilised allergen extract tablets for specific immunotherapy. Each sublingual tablet contains: ACARIZAX<sup>®</sup> 12 SQ-HDM, ITULAZAX<sup>®</sup> 12 SQ-BET. 1 / U. Treatment only with a positive clinical history, positive skin prick test and / or positive specific IgE to the relevant allergen. ACARIZAX<sup>®</sup>: Children and adults (5-65 years): treatment of moderate to severe allergic rhinitis induced by house dust mites. ITULAZAX<sup>®</sup>: Adults and children from the age of 5 years: treatment of moderate to severe allergic rhinitis and/or conjunctivitis induced by pollen from the birch homologous group of trees. D: 1 tablet once a day under the tongue. The first dose must be taken under medical supervision. Severe allergic reactions may also occur later during the course of treatment. C1: Hypersensitivity to any of the excipients. Active or poorly controlled autoimmune disorders. Severe and / or unstable asthma. Severe oral inflammation or wounds in the mouth. Confirmed diagnosis and active symptoms of eosinophilic oesophagitis. W/P: In the event of severe systemic allergic reactions, treatment must be discontinued and a physician contacted immediately. Anaphylactic reactions should primarily be treated with adrenaline, although interactions with other medications may occur (e.g., beta-blockers, tricyclic antidepressants, MAO inhibitors and/or COMT inhibitors). Isolated cases of eosinophilic oesophagitis have been reported. IA: Concomitant treatment with symptomatic anti-allergy drugs may increase the patient's tolerance level. P/L: Treatment should not be initiated during pregnancy or lactation. EADOM: No corresponding studies have been performed. UE: Mild to moderate, mostly transient local reactions are to be expected (e.g., irritation of the mouth and throat, pruritus, swelling, headache, malaise). Severe local allergic reactions and even anaphylaxis may occur. O: Doses higher than the recommended daily dose increase the risk of adverse reactions and severe allergic reactions. P: ACARIZAX<sup>®</sup>: 30, 90 tablets. ITULAZAX<sup>®</sup>: 30, 90 tablets. Dispensingcategory: A. Informationstatus: ACARIZAX<sup>®</sup> 05-2025, ITULAZAX<sup>®</sup> 05-2025. See current information for healthcare professionals at [www.swissmedinfo.ch](http://www.swissmedinfo.ch). ALK-Abello AG, Richtstrasse 11, 8304 Wallisellen, Switzerland, phone +41 44 908 21 00, [www.alk.net/ch](http://www.alk.net/ch)

Healthcare professionals can request a complete copy of the cited study publications from the pharmaceutical company.



Richtstrasse 11, 8304 Wallisellen  
Tel. +41 44 908 21 00, [info@alk.net](mailto:info@alk.net),  
[www.alk.net/ch](http://www.alk.net/ch)

CH-42X-2500013-0725

# Anzupgo<sup>®</sup> NOW

- “ The first and only **topical pan-JAK inhibitor**<sup>1</sup>
- “ For **all forms of moderate to severe chronic hand eczema** in adults<sup>2</sup>
- “ When topical corticosteroids are not sufficient or not recommended<sup>2</sup>

**NEW**  
available and  
reimbursable  
without prior  
reimbursement  
request (KoGu)

**Referenzen:** 1. Bissone R, et al. Efficacy and safety of delgocitinib cream in adults with moderate to severe chronic hand eczema (DELTA 1 and DELTA 2): results from multicentre, randomised, controlled, double-blind, phase 3 trials. The Lancet. 2024; 404(10430):461-473. 2. Fachinformation Anzupgo<sup>®</sup> (Delgocitinib). [www.swissmedinfo.ch](http://www.swissmedinfo.ch) 3. BAC. Spezialistenliste. [www.spezialistenliste.ch](http://www.spezialistenliste.ch)

**Anzupgo<sup>®</sup> - C:** Cream, white to slightly brown. Active substance: 20mg/g delgocitinib. Excipients: 10 mg/g benzyl alcohol (E1519), 0.2 mg/g butylhydroxyanisole (E320), 72 mg/g cetostearyl alcohol, citric acid monohydrate, sodium edetate, hydrochloric acid, liquid paraffin, macrogol 22 cetostearyl ether, purified water. E: moderate to severe chronic hand eczema in adults who have had an inadequate response to, or for whom a treatment with potent to very potent topical corticosteroids is not recommended. D/Adm.: Apply twice daily a thin layer to the affected skin area of hands and wrists until the skin is clear or almost clear. In the event of recurrence of signs and symptoms, twice daily treatment of affected areas may be re-initiated as needed. N: more than 1 tube per month. C1: Hypersensitivity to the active substance or to any of the excipients. W/P: Close monitoring for signs of infection; monitoring for signs of TB. Interruption in case of a serious, an opportunistic infection or sepsis, in case of herpes zoster. Discontinuation in case of myocardial infarction or stroke in case of symptoms of thrombosis in case of clinically significant thrombocytopenia, anaemia and neutropenia. Avoid in case of increased risk of thrombosis. Periodic skin examination recommended, particularly in patients with risk factors for skin cancer. Wearing protective clothing and using broad spectrum sunscreens for protection against sunlight and UV light exposure. Avoid direct skin contact to other persons right after application. Avoid contact with healthy skin, eyes, mouth or other mucous membranes. If contact occurs, rinse thoroughly with water. IA: Low risk for potential interaction with systemic medicinal products. Concomitant application with other topical or the same skin area is not recommended. P/L: Do not use during pregnancy and lactation. UE: Common Application site reactions. Precautions for storage: Do not store above 30°C. Do not freeze. P: Tube with 60 g ± 1 g. Date of information: June 2024. \*Reimbursed ([www.spezialistenliste.ch](http://www.spezialistenliste.ch)).

▼ This medicinal product is subject to additional monitoring. For further information, see Product Information/Patient Information Anzupgo<sup>®</sup> on [www.swissmedinfo.ch](http://www.swissmedinfo.ch).

For more detailed information please consult the current Product Information on [www.swissmedinfo.ch](http://www.swissmedinfo.ch).

All studies / references can be requested from the company (see postal address).

© LEO Pharmaceutical Products Sarath Ltd., Postbox, The Circle 6, 8058 Zurich.  
LEO and the LEO Lion Design are registered trademarks of LEO Pharma A/S. LEO® ©2025 LEO Pharma Inc. All rights reserved. MAT-83489 June 2025





# PROGRAMME – THURSDAY, AUGUST 28<sup>TH</sup>, 2025

<b>09:00 - 09:45</b>	<b>Registration</b>
<b>09:45 - 09:50</b> Rome	<b>Welcome</b> Camillo Ribí, Lausanne; Julia Esser-von Bieren, Epalinges
<b>09:50 - 11:00</b> Rome	<b>Plenary 1: Autoimmunity</b> Sanjiv Luther, Epalinges; Yannick Muller, Lausanne
 MIX: Fundamental & Clinical Science	<b>New Insights into B Cell-Driven Autoimmunity</b> Carola Vinuesa, London (GB) <b>Resetting Autoimmunity in Immune-Mediated Autoimmune Disease</b> Gerhard Krönke, Berlin (DE)
<b>11:00 - 11:20</b>	<b>Coffee break with industry exhibition</b>
<b>11:20 - 12:30</b> Rome	<b>Plenary 2: Host Immunity, Epithelial Barriers and Microbiome</b> Isabelle Arnold Wallén, Zürich; Ping-Chih Ho, Lausanne
 MIX: Fundamental & Clinical Science	<b>Host Immunity and the Microbiome</b> Yasmine Belkaid, Paris (FR) <b>Modulation of Human Immunity by T Cell Cross-Reactivity: from Commensals to Intestinal Food Antigens</b> Petra Bacher, Kiel (DE)
<b>12:30 - 14:00</b>	<b>Lunch break with industry exhibition</b>
<b>12:45 - 13:45</b> St. Moritz B	<b>Guided Poster Tour</b> Camillo Ribí, Lausanne; Matthieu Perreau, Lausanne
	<b>A05 Early-Life Lung Microbial Dysbiosis Shapes Immune Responses and Predisposes to Allergic Airway Inflammation</b> Kirby Rutherford Frank, Lausanne
	<b>A06 Immunogenicity Assessment of Eggplant Mosaic Virus-Based Virus-Like Particle Vaccines Displaying Fel d 1 Administered Through Different Routes in Mice</b> Mahsa Asgari, Bern
	<b>C01 A Helminth-Based Biologic Targets Eicosanoid Pathways and Modulates Type-2 Inflammation</b> Sina Bohnacker, Lausanne
	<b>L01 Machine Learning Classification Based on a 15-Autoantibody Profile by a Fully Automated Multiplex Microarray Immunoassay for Autoimmune CTD Diagnosis</b> Gerber Gomez, Eysins
	<b>L04 The Cytokine-Based Lymphocyte Transformation Test (Cyto-LTT) – Evaluating Quality and Strength of T Cell Reactions to Drugs in Vitro</b> Tim Peyer, Bern
	<b>B32 Architects of Immunity: Notch2-Dependent Crosstalk Between Lymph Node Fibroblasts and CCR7<sup>+</sup> Dendritic Cells Shapes the T Cell Niche</b> Marija Jokic, Epalinges

Company Symposium 1, Thursday, August 28, 2025

13:00 – 13:45





Room St. Moritz A

# Exploring New Horizons in Hereditary Angioedema (HAE) Treatment: Innovations and Future Perspectives

**Otsuka Pharmaceutical (Switzerland) GmbH**

Sägereistrasse 20 | 8152 Glattbrugg | Switzerland | Tel. : +41 43 211 61 11 |  
info@otsuka.ch | www.otsuka.ch

# PROGRAMME – THURSDAY, AUGUST 28<sup>TH</sup>, 2025

13:00 - 13:45		Company Symposia	
St. Moritz A	<b>Company Symposium 1</b> Florian Stehlin, Lausanne		
	<b>Exploring New Horizons in Hereditary Angioedema (HAE) Treatment: Innovations and Future Perspectives</b> Urs Steiner, Bern Otsuka Pharmaceutical (Switzerland) GmbH		
Turin AB	<b>Company Symposium 2</b> Oliver Fuchs, Luzern		
	<b>Innovations in Pediatric Allergology: Newly Approved Tree Pollen and HDM AIT Therapies</b> Felicitas Bellutti Enders, Basel; Maria Breiding, Zürich ALK-Abelló AG		
14:00 - 15:30			
Parallel Sessions 1-3			
Rome	<b>Parallel Session 1: Allergy (Respiratory)</b> Milena Sokolowska, Davos; Niki Ubags, Lausanne		
 MIX: Fundamental & Clinical Science	<b>Epithelial Barrier Theory and the Development of Allergic, Autoimmune and Neuropsychiatric Diseases</b> Cezmi Akdis, Davos Wolfgang  <b>Macrophage Memory as a Driver of Type 2 Inflammatory Diseases</b> Julia Esser-von Bieren, Epalinges  <b>Location Matters: Defining the Architecture of the Bronchial Wall in Health and Asthma</b> Clare Lloyd, London (GB)		
St. Moritz A	<b>Parallel Session 2: Tumor-Immunology</b> Camilla Jandus, Genève; Denarda Dangaj, Lausanne		
 FUN: Fundamental Science	<b>Unveiling the Mechanisms of TIL Therapy: Toward Next-Generation Approaches</b> Alexandre Harari, Lausanne  <b>Targeting Malignant Glioma Immunomatrix with Engineered Immune Cells</b> Denis Migliorini, Genève  <b>Local Mechanisms Regulating Anti-Cancer Immunity in Tumors</b> Jan Böttcher, Tübingen (DE)		



## HyQvia® – for flexible use at home for adults

HyQvia® – hyaluronidase-facilitated subcutaneous immunoglobulin treatment for PID and SID<sup>1</sup>

**PID:** Primary Immunodeficiency; **SID:** Secondary Immunodeficiency.

**Reference:** 1. Prescribing information HyQvia®, www.swissmedicinfo.ch.

**HyQvia®**

C: 100 mg/ml immunoglobulinum humanum normal (SClg) (min. 98 % IgG), hyaluronidasum humanum ADN. I: Replacement therapy in adults in primary immunodeficiency syndromes with impaired antibody production or secondary immunodeficiencies (SID) in patients who suffer from severe or recurrent infections, ineffective antimicrobial treatment and either proven specific antibody failure (PSAF) or serum IgG level of <4 g/l. D: Dosage should be individualized to each patient based on pharmacokinetic and clinical response. Subcutaneous Administration. C: Intravenous and intramuscular administration. Hypersensitivity reactions to the active ingredient (IgG) or any of the other ingredients. Hypersensitivity to human immunoglobulins, especially IgA deficiency with concomitant presence of anti-IgA antibodies. Known systemic hypersensitivity to hyaluronidase or recombinant human hyaluronidase. PR: Shock possible with intravenous administration. Adhere to infusion rate. Monitor patients throughout the infusion period. Potential complications can often be avoided by slow initial infusion. IA: Administration of immunoglobulin may interfere with the efficacy of live vaccines. PR/LACT: Use with caution during pregnancy and breastfeeding, only after carefully weighing the benefits and risks. UE: HyQvia® and analog IV product: very common (≥1/10): rash (11.8 %), local reactions (21.9 %). Common (≥1/100, <1/10): Anemia, lymphadenopathy, decreased appetite, anxiety attacks, headache, insomnia, hypoesthesia, conjunctivitis, tachycardia, rhinorrhea, nasal congestion, oropharyngeal pain, dyspnea, vomiting, nausea, abdominal pain, Diarrhea, dyspepsia, bruising, dermatitis, myalgia, chest pain affecting skeletal muscles, muscle cramps, muscle weakness, local reactions, fever, weakness, chest discomfort, chest pain, rigor. Other relevant UEs: aseptic meningitis, thromboembolic events were observed, as well as hemolytic anemia/hemolysis. Hypotension with anaphylactic reaction is rare but may occur even if the patient has not shown hypersensitivity with previous administrations. P: Each package contains 1 vial of Ig 100 mg/ml and 1 vial of recombinant human hyaluronidase: 25 mg/1.25 ml; 50 mg/2.5 ml; 100 mg/5 ml; 200 mg/10 ml; 300 mg/15 ml. Dispensing category B; remunerated by the health insurance fund. **Marketing authorization holder:** Takeda Pharma AG, 8152 Opfikon. For further information: see prescribing information (www.swissmedicinfo.ch). C-APROM/CH/HYQ/0001

## REIMAGINE THE WAY YOU TREAT HAE



- **TAKHZYRO® IS NOW APPROVED FOR LTP THERAPY FOR A BROAD AGE RANGE OF PATIENTS<sup>1</sup>**
- **THE SPRING PHASE III STUDY\* DEMONSTRATED A FAVORABLE SAFETY AND EFFICACY PROFILE OF TAKHZYRO® IN PEDIATRIC PATIENTS WITH HAE<sup>2</sup>:**
  - There were no reported serious treatment-emergent adverse events or discontinuations resulting from such events<sup>2</sup>
  - Effective attack prevention with a 95 % reduction in HAE attacks compared to baseline<sup>2</sup>
  - Improvement in QoL under Takzhryo®: PedsQL, PedsQL-FIM and EQ-5D-Y questionnaires demonstrated an improvement of QoL for pediatric HAE patients and their caregivers<sup>2</sup>

\* The SPRING Study was an open-label, multicenter phase III study, and evaluated as primary endpoint the safety and pharmacokinetics of lanadelumab in 21 children aged 2 to < 12 years with HAE

**EQ-5D-Y:** EuroQol 5-Dimension Youth Scale; **HAE:** hereditary angioedema; **LTP:** long-term prophylaxis; **PedsQL:** Pediatric Quality of Life Inventory Generic Core Scale; **PedsQL-FIM:** Pediatric Quality of Life Inventory Generic Core Scale Family Impact Module; **QoL:** quality of life

**References:** 1. Prescribing information Takzhryo®, www.swissmedicinfo.ch. 2. Maurer M, et al. Lanadelumab in Patients 2 to Less Than 12 Years Old With Hereditary Angioedema: Results From the Phase 3 SPRING Study. J Allergy Clin Immunol Pract. 2024 Jan;12(1):201-211.e6. Healthcare professionals may request a complete copy of the cited literature from the pharmaceutical company.

**Takzhryo®**

Z: Lanadelumabum. Recombinant human IgG1 monoclonal antibody. I: For long-term prophylaxis of hereditary angioedema (HAE) attacks in patients 2 years and older. D: From 12 years: The recommended dose is 300 mg every 2 weeks as a subcutaneous injection. A dose interval of 300 mg every 4 weeks is also effective and may be considered if the patient has been well controlled (e.g., has not suffered attacks) for more than 6 months. From 6 to < 12 years: The recommended dose is 150 mg every 2 weeks. A dose interval of 150 mg every 4 weeks is also effective and may be considered if the patient has been well controlled for more than 6 months (e.g., has not suffered any attacks). From 2 to < 6 years: The recommended dose is 150 mg every 4 weeks. C: Hypersensitivity to the active ingredient or to any of the other ingredients. PR: Hypersensitivity reactions: As with any monoclonal antibody, more severe reactions may occur with, e.g. hypotension, tachycardia, dizziness, dyspnea, nausea, urticaria, and other skin symptoms; interference with coagulation tests: increase in aPTT without change in INR and not associated with adverse bleeding events. IA: No studies have been conducted to detect interactions. CYP enzyme-mediated interactions are unlikely. ADR: Very common (≥ 1/10): injection site reactions, common (≥ 1/100, < 1/10): hypersensitivity, dizziness, maculopapular rash, myalgia, alanine aminotransferase (ALT) increased, aspartate aminotransferase (AST) elevated. For more information on ADRs, see: SmPC. PB: Takzhryo should not be used during pregnancy unless clearly necessary. GF: 150 mg/ml solution for injection. 2 ml: pack with 1 prefilled syringe, 1 ml: pack with 1 prefilled syringe. Dispensing category: B. **Marketing authorization holder:** Takeda Pharma AG, 8152 Opfikon. For further information: see prescribing information (www.swissmedicinfo.ch). C-APROM/CH/TAKH/0001



Better Health, Brighter Future

Visit our website for  
**healthcare  
professionals**



[takedapro.ch](https://takedapro.ch)



# PROGRAMME – THURSDAY, AUGUST 28<sup>TH</sup>, 2025

Turin AB	<b>Parallel Session 3: Immune Defects</b> Mike Recher, Basel; Jana Pachlopnik, Zürich
 CLI: Clinical Science	<b>Human ADA2 Deficiency</b> Isabelle Meyts, Leuven (BE)  <b>BMT in Severe Immune Deficits</b> Tayfun Güngör, Zürich  <b>Inborn Errors of Immunity in Inflammatory Bowel Disease</b> Holm Uhlig, Oxford (GB)
<b>15:30 - 16:00</b>	<b>Coffee break with industry exhibition</b>
<b>16:00 - 17:00</b>	<b>Short Communication Sessions</b>
St. Moritz A	<b>Short Communication Session – Clinical Immunology &amp; Allergy</b> Onur Boyman, Zürich; Gerhard Krönke, Berlin (DE)
 MIX: Fundamental & Clinical Science	<b>SC07 Dupilumab Treatment is Associated with a Shift Towards a Health-Associated Nasal Passage Microbiota in Diffuse Type 2 Chronic Rhinosinusitis</b> Fabio S. Ryser, Bern  <b>SC08 PLGA-Microsphere Based T-Cell Vaccination Against Influenza: A Virus.</b> Dennis Mink, Konstanz (DE)  <b>SC09 Type 2 Inflammatory Microenvironment in Patients with Chronic Rhinosinusitis with Nasal Polyposis: Exploring Before and After 12 Months of Dupilumab</b> Eusebiu Marian Latis; Pieve Emanuele, Milan (IT)  <b>SC10 A Collaborative Care Model for Patients with Primary Immunodeficiency – Update on a Swiss Model with Comprehensive Genetic Characterization</b> Mike Recher, Basel  <b>SC11 Harnessing an Epigenetic Rewiring Technique to Tailor T Cell Differentiation for Controlling Colitis and Tumors</b> Lorène Rousseau, Epalinges  <b>SC12 Targeting Type 2 Cytokines Alters Epigenetic Reprogramming of Eosinophil Progenitors in Severe Asthma</b> Isika Ram, Epalinges

# PROGRAMME – THURSDAY, AUGUST 28<sup>TH</sup>, 2025

Rome

## Short Communication Session – Allergology

Sina Bohnacker, Lausanne; Cezmi Akdis, Davos Wolfgang



MIX: Fundamental  
& Clinical Science

### SC01 The Bacterial Lysate OM-85 Mitigates HDM-Induced Allergic Inflammation Through the Airway Epithelial Cell-Macrophage Crosstalk

Athanasios Kouklas, Lausanne

### SC02 Type 1 IFNs Drive Trained Immunity in Asthma

Eya Ben Salah, Lausanne

### SC03 Characterization of Young Children with Food Allergy in Northwestern Switzerland

Anna Salem, Basel

### SC04 Predicting Tolerance and Intolerance in Pediatric Hazelnut Oral Food Challenges: A Cohort Analysis

Maria Breiding, Zurich

### SC05 The Impact of Obesity in Asthma and Small Airway Dysfunction: Prevalence, Clinical characteristics, and Predictors

Christina Marie Arpajian; Pieve Emanuele, Milan (IT)

### SC06 Protein Profiles of Children with Food Allergies

Michèle S. Roth, Basel

17:00 - 17:15

Room change

17:15 - 18:15

SSAI General Assembly

From 18:00

Congress Dinner at the «Olympic Museum Lausanne»

18:00 - 20:00

Exclusive access to the Olympic Museum – explore captivating exhibits and the spirit of Olympism.

19:00 - 20:00

Apéritif on the terrace (weather permitting), with a beautiful view of Lake Geneva.

20:00

Congress Dinner at the «Olympic Museum in Lausanne»



CSL Behring

YOUR MISSION:  
CONTROL HAE

YOUR GADGET:  
ANDEMBRY®

NEW HAE  
PROPHYLAXIS\*

SUI-AND-0069/05/2025

\*ANDEMBRY® is indicated for the long-term prophylaxis of recurrent acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged 12 years and older (see «Warnings and precautions» and «Clinical efficacy»). ANDEMBRY®: Garadacimab (human, monoclonal IgG4 antibody against activated factor XII); 200 mg solution for injection in a pre-filled pen for subcutaneous use. Dispensation category B. Detailed information about the product from the marketing authorization holder CSL Behring AG, Wankdorfstrasse 10, 3014 Bern, can be found at [www.swissmedicinfo.ch](http://www.swissmedicinfo.ch) (information status: 01/2025).

ANDEMBRY®  
garadacimab

## It's time to raise the standard

In Lupus care

### Systemic lupus erythematosus (SLE)

**EULAR 2023 Guidelines** also recommend Benlysta before immunosuppressants in case of non-response to HCQ or failure to reduce steroids to ≤5mg/day<sup>1</sup>

### Lupus Nephritis (LN)

**EULAR 2023 and KDIGO 2024 Guidelines** recommend Benlysta for initial and maintenance treatment of active proliferative LN<sup>1</sup> class III/IV +/-V<sup>2</sup>

Benlysta is the **only approved biologic** for the treatment of SLE and LN<sup>3</sup> that has been shown to prevent organ damage in SLE.<sup>4,5</sup>

This fictitious patient image is for illustrative purposes only

Detailed information about Benlysta, its indication and safety profile can be found at [www.swissmedicinfo.ch](http://www.swissmedicinfo.ch). Please report adverse drug reactions under [pv.swiss@gsk.com](mailto:pv.swiss@gsk.com). Specialised persons can request the mentioned references from GlaxoSmithKline AG.

HCQ = Hydroxychloroquin; LN = Lupusnephritis; SLE = Systemischer Lupus erythematosus.

# Two propensity score-matched analyses have shown a significantly lower probability of increasing organ damage with Benlysta + standard therapy than with standard therapy alone.<sup>3,4</sup>  
**References:** 1. Fanouriakis A et al. EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann Rheum Dis. 2024; 83(1):15-29. 2. Kidney Disease: Improving Global Outcomes (KDIGO) Lupus Nephritis Work Group. KDIGO 2024 Clinical Practice Guideline for the Management of Lupus Nephritis. Kidney Int. 2024;105(1S):S1–S69. 3. SmPC Benlysta (Sep 2024). GlaxoSmithKline AG, [www.swissmedicinfo.ch](http://www.swissmedicinfo.ch) (last viewed May 2025). 4. Urowitz MB et al. Organ damage in patients treated with belimumab versus standard of care: a propensity score-matched comparative analysis. Ann Rheum Dis. 2019; 78(3):372-379. 5. Urowitz MB et al. Comparative analysis of long-term organ damage in patients with systemic lupus erythematosus using belimumab versus standard therapy: a post hoc longitudinal study. Lupus Sci Med. 2020; 7(1):e000412.




Trademarks are the property of their respective owners. ©2025 GSK group of companies or its licensor. GlaxoSmithKline AG, Talstrasse 3, 3053 Münchenbuchsee.

Benlysta  
(belimumab)



PM-CH-BEL-ADV-2501-05/2025

# PROGRAMME – FRIDAY, AUGUST 29<sup>TH</sup>, 2025

<b>08:15 - 09:00</b>	<b>Registration</b>
<b>09:00 - 10:30</b>	<b>Parallel Sessions 4 - 6</b>
St. Moritz A	<b>Parallel Session 4: Neuro-Immunology</b> Sarah Mundt, Zürich; Amandine Mathias, Lausanne
 MIX: Fundamental & Clinical Science	<b>Lasting Impressions: Long-Term Effects of Immune–Neuronal Interactions in the CNS</b> Doron Merkler, Genève <b>Identifying and Disrupting Neuro-Immune Circuits in Cancer</b> Karen Dixon, Basel <b>Exploring the Gut-Brain Axis in Neuroimmunological Diseases</b> Caroline Pot, Lausanne
Turin AB	<b>Parallel Session 5: Diagnostics</b> Matthieu Perreau, Lausanne; Luca Bernasconi, Aarau
 CLI: Clinical Science	<b>Immunomonitoring in Oncology</b> Michel Obeid, Lausanne <b>Cell-Free DNA – Current and Potential Applications</b> Jakob Nilsson, Zürich <b>Autoreactome Profiling for Immune Pathogenesis Understanding Immune Resetting</b> Elisabetta Traggiai, Basel
Rome	<b>Parallel Session 6: Mucosal Immunity &amp; Infection</b> Philippe Krebs, Bern; Fabienne Tacchini-Cottier, Lausanne
 FUN: Fundamental Science	<b>Antibodies and Autoantibodies After Viral Infection</b> Davide Robbiani, Bellinzona <b>Eosinophils in Intestinal Homeostasis and Inflammation</b> Isabelle Arnold Wallén, Zürich <b>Getting Dirty: A Dampen on Type 2 Immunity</b> Tiffany Bouchery, Allschwil
<b>10:30 - 11:00</b>	<b>Coffee break with industry exhibition</b>

# CONGRESS DINNER AT THE «OLYMPIC MUSEUM»



Thursday, August 28<sup>th</sup>, 2025

We are delighted to invite you to the Congress Dinner 2025 in Lausanne – an evening of celebration, inspiration, and meaningful connections.

The event takes place at the stunning Olympic Museum, where we'll immerse ourselves in the rich history of both the ancient and modern Olympic Games.



## SCHEDULE

**18:00**

Exclusive access to the Olympic Museum – explore captivating exhibits and the spirit of Olympism.

**19:00**

Apéritif on the terrace (weather permitting), with a beautiful view of Lake Geneva.

**20:00**

Congress Dinner

## COSTS

CHF 120.00 per person

## LOCATION

Olympic Museum, Quai d'Ouchy 1  
1006 Lausanne, Switzerland

Bus transfer to the Olympic Museum is provided

## REGISTRATION

To attend the Congress Dinner, please register through the congress registration.

**Reserve your seat now – and experience the spirit of Olympism!**

11:00 – 12:00 Short Communication Sessions	
St. Moritz A	<b>Short Communication Session – Basic Immunology</b> Christoph Scheiermann, Genève; Manuele Rebsamen, Lausanne
 FUN: Fundamental Science	<b>SC13 Dysfunctional Mitochondria Promotes DNA Damage and T Cell Exhaustion in CD8+ T Cells</b> Kung-Chi Kao, Epalinges  <b>SC14 Training Improves Antimicrobial Innate Immune Defenses in Aged Mice</b> Charly Gilbert, Epalinges  <b>SC15 Tailoring T Cell Anti-Tumor Immunity in Hepatocellular Carcinomas by Exploiting Kupffer Cell-Guided Priming</b> Jaehoh Park, Epalinges  <b>SC16 The Role of Regulatory Factor X7 in B Cell Activation and Lymphomagenesis</b> Hanif Javanmard Khameneh, Bellinzona  <b>SC17 CCDC134 Controls TLR Biogenesis Through the ER Chaperone Gp96</b> Léa Bernaleau, Epalinges  <b>SC18 Skin TSLP Acts on Non-Canonical DC Population to Promote GATA3+ Treg</b> Marine Guivarch, Strasbourg (FR)
Turin AB	<b>Short Communication Session – Translational</b> Camilla Jandus, Genève; Déla Golshayan, Lausanne
 MIX: Fundamental & Clinical Science	<b>SC19 Neutrophil-Mediated Melanoma Cell Killing in Adjuvant Antibody Therapy</b> Mette-Triin Purde, St. Gallen  <b>SC20 Autophagy in Dendritic Cells Impacts Immunosenescence</b> David Cune, Lausanne  <b>SC21 Targeting IFN-γ-Driven DCs to Harness Type-2 Immunity Against Tumor Resistance</b> Tzu-Hsuan Chang, Epalinges  <b>SC22 Mapping Intestinal Development and Function with Spatiotemporal Analysis and Organ-on-a-Chip Models</b> Verena Lentsch, Oxford (GB)  <b>SC23 Dysregulations in L-Phenylalanine Metabolism Facilitate Pro-Inflammatory Th2 Phenotype in Severe Allergy</b> Abhijeet Kulkarni, Davos-Wolfgang  <b>SC24 Tumor Specific Regulation of T Cell Exhaustion Can Be Targeted for Immunotherapy</b> Gregory Verdeil, Epalinges

# PROGRAMME – FRIDAY, AUGUST 29<sup>TH</sup>, 2025

11:00 - 12:00	<b>TARDOC – What to Expect – How to Prepare?</b> Christophe Weilenmann, Porrentruy
Rome	<b>What to Expect – How to Prepare?</b> Christophe Weilenmann, Porrentruy; Miro Räber, Zürich; Giovanni Ferrari, Lugano; Martin Glatz, Uster  <b>Discussion</b>
12:00 - 13:30	<b>Lunch break</b>
12:15 - 13:15	<b>Guided Poster Tour</b> Julia Esser-von Bieren, Epalinges; Thierry Roger, Lausanne
St. Moritz B	<p><b>B14 IL-33-Mediated Fibroblast-myeloid Cell Crosstalk Controls Intestinal Granuloma Formation</b> Elke Scandella, St.Gallen</p> <p><b>B13 The TLR7/9 Adaptors TASL and TASL2 Mediate IRF5-Dependent Antiviral Responses and Autoimmunity</b> Aleš Drobek, Lausanne</p> <p><b>B15 Hookworm Infection Induces Long-Term Changes in the Epithelial Compartment of the Lungs</b> Dovran Ovezgeldiyev, Allschwil</p> <p><b>B17 Metabolic Regulation of Epithelial RIG-I Signaling in Viral Exacerbations of Asthma</b> Urszula Radzikowska, Davos</p> <p><b>B26 Deciphering the Role of Hedgehog Signaling in Medullary Reticular Cells During Lymph Node Homeostasis</b> Marija Jokic, Epalinges</p> <p><b>B27 Environmental Interference in the Fight Against Respiratory Aspergillus Infection</b> Aurélien Trompette, Epalinges</p>
12:30 - 13:15	<b>Company Symposia 3 - 4</b>
Rome	<b>Company Symposium 3</b> Florian Stehlin, Lausanne  <b>Challenges of Angioedema Therapy in Different Stages of Life</b> BioCryst Schweiz GmbH, Zug Christina Weber, Zürich; Isabelle Boccon-Gibod, Grenoble (FR)
St. Moritz A	<b>Company Symposium 4</b>  <b>Allergen Immunotherapy: Bridging Science and Patient Experience</b> Stallergenes AG Peter Schmid-Grendlmeier, Zürich; Oliver Fuchs, Luzern



# PROGRAMME – FRIDAY, AUGUST 29<sup>TH</sup>, 2025

13:30 – 15:00		Parallel Sessions 7 - 8
St. Moritz A		<b>Parallel Session 7: Hypersensitivity and Immune Regulation</b> Jeremy Di Domizio, Lausanne; Lukas Jörg, Bern
 CLI: Clinical Science		<b>T Regulatory Cell-Targeting Immunotherapy of Immune-Mediated Disorders</b> Onur Boyman, Zürich  <b>Recent Advances in Management of Mastocytosis</b> Karin Hartmann, Basel  <b>Skin Barrier Dysfunction in Atopic Dermatitis and Allergic Diseases</b> Caroline Roduit, Bern
Rome		<b>Parallel Session 8: Novel Technologies in Immunology</b> Juliana Ivanisevic, Lausanne; Melita Irving, Lausanne
 FUN: Fundamental Science		<b>Targeted Spatial Metabolomics for Multimodal Imaging of the Airways</b> Craig Wheelock, Stockholm (SE)  <b>Next-Generation Organoids for Cancer Immunotherapy</b> Matthias Lütolf, Lausanne  <b>Type 2 Immunity May Hold Key to Long-Term Cancer Remission</b> Li Tang, Lausanne
13:30 – 14:30		Short Communication Sessions
Turin AB		<b>Short Communication Session – SYIS</b> Verena Lentsch, Oxford (GB); Urszula Radzikowska, Davos
 FUN: Fundamental Science		<b>SC25 The IL-9-IL-18 Axis Drives Th2 Activation in Atopic Dermatitis</b> Stefanie Schärli, Bern  <b>SC26 Vaccine-Enhanced Competition Permits Rational Bacterial Strain Replacement in the Gut</b> Verena Lentsch, Oxford (GB)  <b>SC27 IL-15 Enhances Innate Lymphoid Cell-Mediated Anti-Tumor Immunity in Brain Metastasis</b> Pascal Naef, Irvine (US)  <b>SC28 The Endolysosomal SLC15A4/TASL Complex Activates IRF5-Mediated Th1 Responses Needed to Control Leishmania Major Infection and to Induce Colitis</b> Marta Monguió Tortajada, Epalinges  <b>SC29 Innate Immune Memory and Metabolic Reprogramming in the Lower Airway Epithelium of Patients with Allergic Asthma</b> Ines Jardon Parages, Davos

### Brunello Wüthrich Award

Brunello Wüthrich – aha! Neurodermitis (Atopic dermatitis) Research Prize for the **BEST POSTER PRESENTATION ON EPIDEMIOLOGICAL, CLINICAL OR IMMUNOLOGICAL RESEARCH IN ATOPIC DERMATITIS** (amount of CHF 1'000.–)



ALLERGIEZENTRUM SCHWEIZ  
CENTRE D'ALLERGIE SUISSE  
CENTRO ALLERGIE SVIZZERA



Société Suisse d'Allergologie et d'Immunologie  
Schweizerische Gesellschaft für Allergologie und Immunologie  
Swiss Society for Allergy and Immunology

### Biotest (Schweiz) AG Awards

#### «SCIENCE MEETS QUALITY»

Three Biotest Awards, each valued at CHF 1'000.–, will be presented for the best posters in the categories of «Basic Immunology», «Clinical Immunology» and «Allergology/Allergy or Translational Science».



### Acteria

Fondation ACTERIA offers one CHF 1'000.– award for the best oral presentation each on the following topics during the Annual Congress of the SSAI: Allergology | Clinical Immunology | Basic Immunology | Translational Science



### Sanofi/Regeneron Innovation Award: Novel Approaches in Type 2 Inflammation



With this award, Sanofi supports residents and senior physicians who are clinically active in Allergology/Clinical Immunology in Switzerland and whose translational scientific work deals with the topic of type 2 inflammation and related diseases.

**THE AWARD IS ENDOWED WITH CHF 15'000 AND IS INTENDED FOR THE EXECUTION OF A SCIENTIFIC PROJECT.**





## PROGRAMME – FRIDAY, AUGUST 29<sup>TH</sup>, 2025

15:00 - 15:15	Room change
15:15 - 15:30 Rome	Award Ceremony
15:30 - 16:40 Rome	<b>Plenary 3</b> <b>Keynote Lectures in Clinical Immunology</b> Fabio Candotti, Lausanne; Thierry Roger, Lausanne
 MIX: Fundamental & Clinical Science	<b>Remote: Inborn Error of Immunity</b> Daniel Kastner, Bethesda (Maryland) (US)  <b>Advances in Diagnosis and Treatment of Inflammatory Skin Disease</b> Michel Gilliet, Lausanne
16:40 - 16:45 Rome	<b>Closing</b> Camillo Ribì, Lausanne; Greta Guarda, Bellinzona

  
Booth No. 1

**Personalized training for patients and caregivers.**

**Available 24/7 in any emergency.**

**Support with cost approval and prescriptions processing.**

**High-quality care for your patients.**


**Free home delivery of medication and infusion materials.**





# EXIBITHION PLAN

- Visitor flow
- Gold Sponsoring
- Silver Sponsoring
- Bronze Sponsoring
- Welcome Desk



# SPONSORS AND EXHIBITIORS

## Gold sponsors

04



**Takeda Pharma AG, Glattpark**

19



**REGENERON®**

**Sanofi-Aventis (Schweiz) AG, Vernier**

## Silversponsors

34



**Otsuka Pharmaceuticals (Switzerland) GmbH, Glattbrugg**


03



**Biotest (Schweiz) AG, Rapperswil**

## Bronzesponsors

09



**CSL Behring AG, Bern**

05/06



**GlaxoSmithKline AG, Münchenbuchsee**

12



**LEO Pharmaceutical Products Sarath Ltd, Zürich**

10



**ALK-Abelló AG, Wallisellen**

## Exhibitors

ADR-AC GmbH, Bern	28	Sebia Swiss GmbH, Wollerau	13
ALK-Abelló AG, Wallisellen	10	Siemens Healthineers International AG, Zürich	33
Allergopharma, Hüneberg	23	Sonic Suisse, Kriens	35
Astra Zeneca, Baar	26	Stallergenes AG, Dietlikon	11
Axon Lab AG, Baden-Dättwil	16	STEMCELL Technologies, Europe	02
Bencard AG, Greifensee	24	Swiss 3R Competence Centre (3RCC), Bern	25
Biotest (Schweiz) AG, Rapperswil	03	SYIS, Zürich	22
Careformance GmbH, Eschlikon	01	Takeda Pharma AG, Glattpark	04
CSL Behring AG, Bern	09	Thermo Fisher Diagnostics AG, Reinach	27
Euroimmun Schweiz AG, Kriens	14		
GlaxoSmithKline AG, Münchenbuchsee	05/06		
LEO Pharmaceutical Products Sarath Ltd, Zürich	12		
MediService AG, Zuchwil	21	<b>Additional Support</b>	
Moderna Switzerland GmbH, Basel	08	ALK-Abelló AG, Wallisellen	
Octapharma AG, Lachen	07	BioCryst Schweiz GmbH, Zug	
Otsuka Pharmaceuticals (Switzerland) GmbH, Glattbrugg	34	Careformance GmbH, Eschlikon	
Pharming Technologies B.V., Leiden	20	Octapharma AG, Lachen	
RUWAG Handels AG, Bettlach	15	Otsuka Pharmaceuticals (Switzerland) GmbH, Glattbrugg	
Sanofi-Aventis (Schweiz) AG, Vernier	19	Stallergenes AG, Dietlikon	
		Thermo Fisher Diagnostics AG, Reinach	

# GENERAL INFORMATION

## Venue

The Beaulieu Lausanne Congress Center is located in the city center of Lausanne: Beaulieu SA, Avenue des Bergières 10, CH-1004 Lausanne

## Getting to Beaulieu Lausanne

> <https://beaulieu-lausanne.com/en/useful-links/>

## Arrival by public transport

Lausanne's central station, a major railway link in French-speaking Switzerland, is on the Geneva-Zurich line. There are two trains every hour and trains for Berne, Neuchâtel, Fribourg, Sion, Bienne and Basel.

## Arrival by car

Lausanne is located at a motorway junction in French-speaking Switzerland, and the Congress Centre Beaulieu Lausanne is located 5 minutes from the Blécherette exit from the A9 motorway. It has an underground car park with more than 500 spaces.



## Congress language

English (no simultaneous translation)

## Registration

> <https://ssai-congress.ch/registration>

## Credits\*

	SSAI	FAMH	GST/SVS	SGAIM	SGDV/SSDV	SGMO/SSOM	SGR/SSR
28 August	6 Credits	6 Credits	6 Credits	6 Credits	3 Credits	5 Credits	6 Credits
29 August	6 Credits	6 Credits	6 Credits	6 Credits	6 Credits	5 Credits	6 Credits
Total	12 Credits	12 Credits	12 Credits	12 Credits	9 Credits	10 Credits	12 Credits

\*Additional credits are claimed to further societies

## Administrative Organisation

### Medworld AG

Ms. Svenja Kahlert

Sennweidstrasse 46, 6312 Steinhausen

Phone: +41 41 748 23 00

E-Mail: [registration@medworld.ch](mailto:registration@medworld.ch)

> [www.medworld.ch](http://www.medworld.ch)

# WE SEE A PROTECTED LIFE IN EVERY LIFE

Our plasma-derived  
therapies support  
our patients to lead  
better lives.



# WE SEE A SECOND LIFE IN EVERY LIFE

Our plasma-derived  
therapies support  
our patients to lead  
better lives.



Wir verbessern das Leben  
betroffener Menschen,  
denn es liegt uns im Blut.

octapharma

Schweizer  Unternehmen



## Intensivmedizin



## Immuntherapie



## Hämatologie

**V.I.n.r. Intensivmedizin:** Albinorm® (Humanalbumin), Atenativ® (Antithrombin III vom Menschen), Octaplex® (Humane Blutgerinnungsfaktoren II, VII, IX, X, Proteine C & S), Fibrinogen® (Humanes Fibrinogen), OctaplasG® (Humanes Plasmaprotein). **Immuntherapie:** Cutaquig® (Normales Immunglobulin vom Menschen (SCIG)), Octagam® 10% (Immunglobulin vom Menschen (IVIG)), **Hämatologie:** Octanate® (plasm. Faktor VIII), Nuwiga® (rec. Faktor VIII, simoctocog alfa), Wilate® (plasm. Faktor VIII und plasm. vWF): Abgabekategorie B; Ausführliche Informationen entnehmen Sie bitte der Fachinformation auf [www.swissmedinfo.ch](http://www.swissmedinfo.ch).

**Zulassungsinhaber:** Octapharma AG, Seidenstrasse 2, CH - 8853 Lachen.